GlassScriptPhysician profile
Nikki Bajaj
NPI 1467893917
$2,422.94
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $41.23 · 2021: $14.37 · 2022: $557 · 2023: $1,105 · 2024: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.00 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $265.60 | 2022 | |
| Janssen Biotech, INC. | $236.94 | 2019-2024 | Darzalex, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $195.29 | 2023-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $184.40 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $167.68 | 2023-2024 | Reblozyl, Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $156.33 | 2021-2023 | Jemperli, Zejula, Ojjaara |
| Mannkind Corporation | $125.00 | 2023 | Afrezza |
| Ambu INC. | $117.88 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.33 | 2023 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $85.73 | 2022-2023 | Tagrisso |
| Ge Healthcare | $81.03 | 2022 | |
| Myriad Genetic Laboratories, INC. | $76.70 | 2023-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $69.22 | 2019-2024 | Lynparza, Keytruda |
| Abbvie INC. | $64.08 | 2019-2023 | Venclexta |
| Celgene Corporation | $60.49 | 2022-2024 | Reblozyl |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.46 | 2019 | |
| Eisai INC. | $48.05 | 2023-2024 | |
| Emd Serono, INC. | $44.83 | 2019-2022 | |
| Pfizer INC. | $31.48 | 2024 | |
| Mirati Therapeutics, INC. | $30.33 | 2023 | Krazati |
| Incyte Corporation | $29.14 | 2022-2023 | Jakafi |
| Puma Biotechnology, INC. | $27.83 | 2019-2024 | |
| Gilead Sciences, INC. | $27.35 | 2022-2024 | |
| Daiichi Sankyo INC. | $17.85 | 2024 | Enhertu |
| Lilly USA, LLC | $16.86 | 2024 | Verzenio, Retevmo, Jaypirca |
| Idorsia Pharmaceuticals US INC | $15.46 | 2023 | Quviviq |
| Partner Therapeutics, INC. | $15.08 | 2019 | |
| Kyowa Kirin, INC. | $14.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.78 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.34 | 2019 | |
| Seagen INC. | $12.05 | 2019 | |
| Emmaus Medical, INC. | $11.41 | 2023 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.